Farmacoepidemiología de los fármacos antagonistas de los receptores de angiotensina (ARA) II en el tratamiento de la hipertensión arterial esencial. méxico / Pharmacoepidemiology of antagonist receptors of the angiotensin (ARA) II in the treatment of essential hypertension. mexico

Epidemiología de la hipertensión arterial: A nivel mundial, se reporta que la prevalencia de hipertensión arterial en población adulta se encuentra entre un 20-27%. Tratamiento farmacológico: Los ARA II ejercen su acción a través del bloqueo de los receptores AT1 de la angiotensina II de forma específica y altamente selectiva y actúan inhibiendo los efectos clásicos desfavorables de angiotensina II. Así, los ARA II antagonizan la acción de la angiotensina II producida por cualquier vía enzimática y no actúan sobre la degradación de las quininas, por lo que no condicionan un aumento de sus niveles en sangre. Además, al bloquear los receptores ATI los ARA II permiten que la angiotensina II circulante se pueda ligar a los receptores AT2, lo que puede añadir un efecto adicional potencialmente muy beneficioso. Estudios de morbimortalidad en Hipertensión con ARA II: La eficacia de los ARA II para disminuir la tensión arterial está demostrada desde hace varios años, tanto en HTA leve como moderada o severa, y en múltiples estudios comparativos estos fármacos muestran una eficacia antihipertensiva similar a la de los IECAS, antagonistas del calcio o betabloqueantes. Por tanto, ante una eficacia antihipertensiva similar y un mejor perfil de tolerabilidad, los ARA II pueden considerarse una familia farmacológica de gran utilidad en el tratamiento actual de la HTA. Conclusiones: La conclusión de los autores de diversos estudios es que los IECA y los ARA-II tienen una efectividad antihipertensiva similar y los IECA, una peor tolerabilidad

Epidemiology of hypertension: Epidemiology of hypertension globally, it is reported that the prevalence of hypertension in adult population is between 20-27%. Pharmacotherapy: ARA II exert their action by blocking AT1 receptors Angiotensin II in a specific and highly selective and act by inhibiting the adverse effects angiotesin II classic. Thus, antagonize the action of angiotensin II produced by any means and do not act on enzymatic degradation of kinins, so do not condition an increase in blood levels. In addition to the ATI receptor blockade ARA II allow the circulating Angiotensin II may be linked to the AT2 receptor, which can add an additional potentially beneficial. Studies of morbidity and mortality in hypertension with ARA II: The efficacy of ARA II for lowering blood pressure is well established for several years, both in mild hypertension and moderate or severe and multiple studies comparing these drugs have shown similar antihypertensive efficacy to that of IECA inhibitors, calcium antagonists or beta-blockers. Therefore, given similar antihypertensive efficacy and better tolerability profile the ARA II may be considered a very useful drug family in the current treatment of hypertension. Conclusions: The conclusion of the authors of several studies is that IECA inhibitors and ARA II have similar antihypertensive effectiveness and IECA inhibitors, poorer tolerability

Development of systematic toxicological analysis using GC-MS in the identification of drugs in blood for clinical and forensic purposes

A rapid auto-identification method was developed to reduce the time required for unknown detection in defined groups of compounds in postmortem biological materials. This was achieved by the creation of an excel sheet containing retention time and retention index of n-alkane mixture [C15 - C36]. Then, a calculated retention index and the retention time for a list of compounds with their target ion, two references ions and their ion ratios were saved in a new method table. The new system will automatically search for and identify any compound in the post-run Gas Chromatography - Mass spectrometry data. The developed method showed a high sensitivity and specificity

Importance of separation and determination of anticoagulants for patient's using warfarin by HPLC

The separation and determination of Warfarin as anticoagulant Coumarin in serum was done, after the extraction by high performance liquid chromatography reverse phase [HPLC-RP], where we have extracted serum with two special methods, they were solid-liquid extraction [SPE: sep-pack plus Cartridge] and liquid-liquid extraction. Methods of extraction were accurate and sensitive depending on qualitative and quantitative studies, that Regression coefficient was 0.9997, Variation coefficient was between 0.3-2% and limit of detection was 1.5 micro g/ ml. The best mobile phase was achieved by 95% methanol, 5% water [pH = 4] using ODS S micro m [4.6 mm x 250 mm] Nucleosil. The determination method was applied to qualify serum Warfarin concentration from patient's serum using it as anticoagulant oral tablets. That method has given good sensitive accurate results which are used in routine clinical control in medical laboratories